Mutation of thyroid hormone receptor-Β in mice predisposes to the development of mammary tumors

Oncogene

Volumn 30, Issue 30, 2011, Pages 3384-3390

  Guigon, C J ^a   Kim, D W ^a   Willingham, M C ^b   Cheng, S Y ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer; mammary tumors; mouse models; Pten; thyroid hormone receptor

Indexed keywords

STAT5 PROTEIN; THYROID HORMONE RECEPTOR BETA; LIGAND; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST HYPERPLASIA; BREAST TUMOR; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL PROLIFERATION; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; MAMMARY GLAND; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; ANIMAL; EXPERIMENTAL NEOPLASM; FEMALE; GENETIC PREDISPOSITION; GENETICS; HYPERPLASIA; METABOLISM; MUTATION; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UDDER;

MUS;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERPLASIA; LIGANDS; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MUTATION; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; THYROID HORMONE RECEPTORS BETA;

EID: 79960844326     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.50     Document Type: Article

References (65)

1. Agarwal DP, Soni TP, Sharma OP, Sharma S. (2007). Synchronous malignancies of breast and thyroid gland: a case report and review of literature. J Cancer Res Ther 3: 172-173. (Pubitemid 350293677)
2. Alberg AJ, Helzlsouer KJ. (1997). Epidemiology, prevention, and early detection of breast cancer. Curr Opin Oncol 9: 505-511. (Pubitemid 27480851)
3. Ali IU, Lidereau R, Callahan R. (1989). Presence of two members of c-erbA receptor gene family (c-erbA beta and c-erbA2) in smallest region of somatic homozygosity on chromosome 3p21-p25 in human breast carcinoma. J Natl Cancer Inst 81: 1815-1820. (Pubitemid 20001426)
4. Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A et al. (2010). Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 42: 454-458.
5. Alvarado-Pisani AR, Chacon RS, Betancourt LJ, Lopez-Herrera L. (1986). Thyroid hormone receptors in human breast cancer: effect of thyroxine administration. Anticancer Res 6: 1347-1351.
6. Banneau G, Guedj M, MacGrogan G, de Mascarel I, Velasco V, Schiappa R et al. (2010). Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations. Breast Cancer Res 12: R63.
7. Barash I. (2006). Stat5 in the mammary gland: controlling normal development and cancer. J Cell Physiol 209: 305-313. (Pubitemid 44484620)
8. Barlow C, Meister B, Lardelli M, Lendahl U, Vennstrom B. (1994). Thyroid abnormalities and hepatocellular carcinoma in mice transgenic for v-erbA. EMBO J 13: 4241-4250. (Pubitemid 24295196)
9. Beatson GT. (1896). On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. The Lancet 2: 162-165.
10. Brinton LA, Hoffman DA, Hoover R, Fraumeni Jr JF. (1984). Relationship of thyroid disease and use of thyroid supplements to breast cancer risk. J Chronic Dis 37: 877-893. (Pubitemid 15153987)
11. Bronnegard M, Torring O, Boos J, Sylven C, Marcus C, Wallin G. (1994). Expression of thyrotropin receptor and thyroid hormone receptor messenger ribonucleic acid in normal, hyperplastic, and neoplastic human thyroid tissue. J Clin Endocrinol Metab 79: 384-389. (Pubitemid 24256523)
12. Conde I, Paniagua R, Zamora J, Blanquez MJ, Fraile B, Ruiz A et al. (2006). Influence of thyroid hormone receptors on breast cancer cell proliferation. Ann Oncol 17: 60-64. (Pubitemid 43033841)
13. Conzen SD. (2008). Minireview: nuclear receptors and breast cancer. Mol Endocrinol 22: 2215-2228.
14. Cotarla I, Ren S, Zhang Y, Gehan E, Singh B, Furth PA. (2004). Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 108: 665-671. (Pubitemid 38076397)
15. Ditsch N, Liebhardt S, Von Koch F, Lenhard M, Vogeser M, Spitzweg C et al. (2010). Thyroid function in breast cancer patients. Anticancer Res 30: 1713-1717.
16. Eilon T, Groner B, Barash I. (2007). Tumors caused by overexpression and forced activation of Stat5 in mammary epithelial cells of transgenic mice are parity-dependent and developed in aged, postestropausal females. Int J Cancer 121: 1892-1902. (Pubitemid 47463151)
17. Eng C. (2002). Role of PTEN, a lipid phosphatase upstream effector of protein kinase B, in epithelial thyroid carcinogenesis. Ann N Y Acad Sci 968: 213-221. (Pubitemid 34721882)
18. Fang F, Antico G, Zheng J, Clevenger CV. (2008). Quantification of PRL/Stat5 signaling with a novel pGL4-CISH reporter. BMC Biotechnol 8: 11.
19. Franceschi S, la Vecchia C, Negri E, Parazzini F, Boyle P. (1990). Breast cancer risk and history of selected medical conditions linked with female hormones. Eur J Cancer 26: 781-785. (Pubitemid 20328547)
20. Furumoto H, Ying H, Chandramouli GV, Zhao L, Walker RL, Meltzer PS et al. (2005). An unliganded thyroid hormone beta receptor activates the cyclin D1/cyclin-dependent kinase/retinoblas-toma/E2F pathway and induces pituitary tumorigenesis. Mol Cell Biol 25: 124-135. (Pubitemid 40039805)
21. Giani C, Fierabracci P, Bonacci R, Gigliotti A, Campani D, De Negri F et al. (1996). Relationship between breast cancer and thyroid disease: relevance of autoimmune thyroid disorders in breast malignancy. J Clin Endocrinol Metab 81: 990-994. (Pubitemid 26083958)
22. Goldman MB, Monson RR, Maloof F. (1992). Benign thyroid diseases and the risk of death from breast cancer. Oncology 49: 461-466. (Pubitemid 23003111)
23. Guigon CJ, Zhao L, Lu C, Willingham MC, Cheng SY. (2008). Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor. Mol Cell Biol 28: 4598-4608. (Pubitemid 351977757)
24. Guigon CJ, Zhao L, Willingham MC, Cheng SY. (2009). PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer. Oncogene 28: 509-517.
25. Hayden TJ, Forsyth IA. (1997). Thyroid hormone binding in rat mammary gland. J Endocrinol 75: 38P-39P.
26. Hedley AJ, Jones SJ, Spiegelhalter DJ, Clements P, Bewsher PD, Simpson JG et al. (1981). Breast cancer in thyroid disease: fact or fallacy? Lancet 1: 131-133. (Pubitemid 11199527)
27. Iavnilovitch E, Cardiff RD, Groner B, Barash I. (2004). Deregulation of Stat5 expression and activation causes mammary tumors in transgenic mice. Int J Cancer 112: 607-619. (Pubitemid 39425940)
28. Jemal A, Siegel R, Xu J, Ward E. (2010). Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
29. Kalache A, Vessey MP, McPherson K. (1982). Thyroid disease and breast cancer: findings in a large case-control study. Br J Surg 69: 434-435. (Pubitemid 12045433)
30. Kaneshige M, Kaneshige K, Zhu X, Dace A, Garrett L, Carter TA et al. (2000). Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc Natl Acad Sci USA 97: 13209-13214.
31. Kuijpens JL, Nyklictek I, Louwman MW, Weetman TA, Pop VJ, Coebergh JW. (2005). Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid 15: 1253-1259. (Pubitemid 41821759)
32. Lemaire M, Baugnet-Mahieu L. (1986). Thyroid function in women with breast cancer. Eur J Cancer Clin Oncol 22: 301-307. (Pubitemid 16127868)
33. Li G, Robinson GW, Lesche R, Martinez-Diaz H, Jiang Z, Rozengurt N et al. (2002a). Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 129: 4159-4170. (Pubitemid 35012500)
34. Li Z, Meng ZH, Chandrasekaran R, Kuo WL, Collins CC, Gray JW et al. (2002b). Biallelic inactivation of the thyroid hormone receptor beta1 gene in early stage breast cancer. Cancer Res 62: 1939-1943. (Pubitemid 34408433)
35. Lin KH, Shieh HY, Chen SL, Hsu HC. (1999). Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol Carcinog 26: 53-61.
36. Lynch ED, Ostermeyer EA, Lee MK, Arena JF, Ji H, Dann J et al. (1997). Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. Am J Hum Genet 61: 1254-1260. (Pubitemid 28046900)
37. Manhes C, Kayser C, Bertheau P, Kelder B, Kopchick JJ, Kelly PA et al. (2006). Local over-expression of prolactin in differentiating mouse mammary gland induces functional defects and benign lesions, but no carcinoma. J Endocrinol 190: 271-285. (Pubitemid 44288365)
38. Meier CA, Dickstein BM, Ashizawa K, McClaskey JH, Muchmore P, Ransom SC et al. (1992). Variable transcriptional activity and ligand binding of mutant beta 1 3,5,3'-triiodothyronine receptors from four families with generalized resistance to thyroid hormone. Mol Endocrinol 6: 248-258.
39. Mittra I. (1974). Mammotropic effect of prolactin enhanced by thyroidectomy. Nature 248: 525-526.
40. Ormandy CJ, Camus A, Barra J, Damotte D, Lucas B, Buteau H et al. (1997). Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev 11: 167-178. (Pubitemid 27081894)
41. Parrilla R, Mixson AJ, McPherson JA, McClaskey JH, Weintraub BD. (1991). Characterization of seven novel mutations of the c-erbA beta gene in unrelated kindreds with generalized thyroid hormone resistance. Evidence for two 'hot spot' regions of the ligand binding domain. J Clin Invest 88: 2123-2130.
42. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM et al. (1999). Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 96: 1563-1568. (Pubitemid 29098491)
43. Puzianowska-Kuznicka M, Krystyniak A, Madej A, Cheng SY, Nauman J. (2002). Functionally impaired TR mutants are present in thyroid papillary cancer. J Clin Endocrinol Metab 87: 1120-1128. (Pubitemid 36121076)
44. Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd J. (1997). Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 57: 3657-3659. (Pubitemid 27381202)
45. Sap J, Munoz A, Schmitt J, Stunnenberg H, Vennstrom B. (1989). Repression of transcription mediated at a thyroid hormone response element by the v-erb-A oncogene product. Nature 340: 242-244. (Pubitemid 19171590)
46. Saraiva PP, Figueiredo NB, Padovani CR, Brentani MM, Nogueira CR. (2005). Profile of thyroid hormones in breast cancer patients. Braz J Med Biol Res 38: 761-765. (Pubitemid 40867516)
47. Silva JM, Dominguez G, Gonzalez-Sancho JM, Garcia JM, Silva J, Garcia-Andrade C et al. (2002). Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene 21: 4307-4316. (Pubitemid 34753837)
48. Simon MS, Tang MT, Bernstein L, Norman SA, Weiss L, Burkman RT et al. (2002). Do thyroid disorders increase the risk of breast cancer? Cancer Epidemiol Biomarkers Prev 11: 1574-1578. (Pubitemid 36020009)
49. Smyth PP. (1993). Thyroid disease and breast cancer. J Endocrinol Invest 16: 396-401. (Pubitemid 23197254)
50. Smyth PP. (1997). The thyroid and breast cancer: a significant association? Ann Med 29: 189-191. (Pubitemid 27292526)
51. Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW. (2000). High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/-mice. Cancer Res 60: 3605-3611. (Pubitemid 30482183)
52. Strain JJ, Bokje E, van't Veer P, Coulter J, Stewart C, Logan H et al. (1997). Thyroid hormones and selenium status in breast cancer. Nutr Cancer 27: 48-52. (Pubitemid 26424315)
53. Suzuki H, Willingham MC, Cheng SY. (2002). Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid 12: 963-969. (Pubitemid 35404130)
54. Takatani O, Okumoto T, Kosano H, Nishida M, Hiraide H, Tamakuma S. (1989). Relationship between the levels of serum thyroid hormones or estrogen status and the risk of breast cancer genesis in Japanese women. Cancer Res 49: 3109-3112. (Pubitemid 19148653)
55. Thormeyer D, Baniahmad A. (1999). The v-erbA oncogene (review). Int J Mol Med 4: 351-358.
56. Tosovic A, Bondeson AG, Bondeson L, Ericsson UB, Malm J, Manjer J. (2010). Prospectively measured triiodothyronine levels are positively associated with breast cancer risk in postmenopausal women. Breast Cancer Res 12: R33.
57. Turken O, NarIn Y, DemIrbas S, Onde ME, Sayan O, KandemIr EG et al. (2003). Breast cancer in association with thyroid disorders. Breast Cancer Res 5: R110-R113.
58. Turkson J. (2004). STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 8: 409-422. (Pubitemid 39359648)
59. Vonderhaar BK. (1999). Prolactin involvement in breast cancer. Endocr Relat Cancer 6: 389-404. (Pubitemid 29459786)
60. Wallin G, Bronnegard M, Grimelius L, McGuire J, Torring O. (1992). Expression of the thyroid hormone receptor, the oncogenes c-myc and H-ras, and the 90 kD heat shock protein in normal, hyperplastic, and neoplastic human thyroid tissue. Thyroid 2: 307-313. (Pubitemid 23054189)
61. Wennbo H, Kindblom J, Isaksson OG, Tornell J. (1997). Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology 138: 4410-4415. (Pubitemid 27408488)
62. Wyszomierski SL, Yeh J, Rosen JM. (1999). Glucocorticoid receptor/signal transducer and activator of transcription 5 (STAT5) interactions enhance STAT5 activation by prolonging STAT5 DNA binding and tyrosine phosphorylation. Mol Endocrinol 13: 330-343. (Pubitemid 29068007)
63. Yen PM. (2001). Physiological and molecular basis of thyroid hormone action. Physiol Rev 81: 1097-1142. (Pubitemid 32606667)
64. Zhang Z, Jones S, Hagood JS, Fuentes NL, Fuller GM. (1997). STAT3 acts as a co-activator of glucocorticoid receptor signaling. J Biol Chem 272: 30607-30610. (Pubitemid 27527489)
65. Zumoff B, O'Connor J, Levin J, Markham M, Strain GW, Fukushima DK. (1981). Plasma levels of thyroxine and triiodothyronine in women with breast cancer. Anticancer Res 1: 287-291. (Pubitemid 12174412)